Helen, Mt. (Good Medical) – Montana lawmakers are considering a bill to lower the prices of prescription drugs for people who buy their health insurance in the market, although companies that sell insurance plans Individual illnesses argued on Friday that this would hamper their efforts to negotiate favorable contracts for the administration of their prescription benefits.
Matt Rosendale, Insurance Commissioner and US Insurance Commissioner, said that pharmaceutical benefit managers are putting too much money in their role as intermediaries between pharmaceutical companies and health insurers and choosing the types of drugs that they will cover according to their importance. discount that they will receive from manufacturers. He said the bill would give insurance companies the regulatory support they need to negotiate more favorable contracts with drug benefit executives.
Rosendale said the drugs were going down a complicated path between the manufacturer and the consumer, with each entity increasing the price along the way.
"We focused on the fact that drug benefit managers are the primary beneficiary of this process," Rosendale told the Senate Labor and Labor Board.
Drug company lobbyists have expressed support for the bill.
Opponents, including insurance companies that sell policies on the federal stock market, say they already dictate the terms of their pharmacy administration contracts and that the proposed law would eliminate some of their options for negotiating better deals. .
The bill would require the amount paid by a health insurer for a prescription drug to be the same amount as that received by the pharmacy and all drug manufacturer rebates be returned to the health insurance companies and used to reduce premiums.
Richard Miltenberger, President and CEO of Montana Health Co-Op, which offers health insurance policies through the market, said his organization had signed a drug benefits management contract, which did not allow the price distribution and included a full impact of drug rebates.
The bill regulates drug benefit managers through insurance companies, who are subject to a fine for violation, which Miltenberger has described as unfair.
Jennifer Hensley, of Pacific Source Health Plans, said, "We are already able to do a lot of the things this bill claims to do for us," adding that the drug companies have "done a fantastic job at it. nationwide by turning the goal "into pharmacy. managers.
Pacific Source uses PBM for claims processing and price bargaining power, she said.
"If you really want to help," she told the committee, "let's explore the transparency of pharmaceutical manufacturers."
The committee did not act on the bill on Friday.
Congress and other states are also trying to develop solutions to deal with the rise in prescription drug prices, that it is to investigate manufacturers or offer to import discounted drugs from Canada. President Donald Trump signed in October a law banning the clauses of pharmacy contracts prohibiting pharmacists from informing consumers when the spot price of a drug is lower than their quota.
Another bill The state legislature seeks to protect pharmacies from "take-or-leave" contracts with drug benefit managers that include sometimes unexpected and retroactive fees and prohibit pharmacies from running a mail-order business.
"There are good players in this game to be a pharmacy intermediary," said Sen. Al Olszewski, doctor and Republican of Kalispell, last week in favor of the Pharmacy Contracts Bill, which was passed by the Senate 49-0. "Good actors are doing what is already in this bill. But there are bad actors who are not.